Schrodinger, Inc. (SDGR)

Over the past six months, Schrödinger's stock price has declined significantly. Key events include analyst downgrades and price target cuts from UBS and Bank of America, a broader market selloff due to geopolitical tensions, ongoing unprofitability with analysts forecasting negative EPS, insider selling by CEO Ramy Farid, a Q4 2025 earnings beat that did not significantly lift the stock, a strategic partnership with Lilly TuneLab, and a transition to a licensing model that is depressing near-term revenue growth.

Demand seasonality for Schrödinger's products and services is influenced by its business segments. The software business can experience seasonality, particularly concerning the timing of pharmaceutical company scale-up opportunities, with the fourth quarter being critical for software bookings and renewals. The drug discovery segment's revenue is driven by milestones and royalties, which may not follow strict seasonal patterns, affecting overall revenue growth.

Schrödinger, Inc. is a scientific software and biotechnology company specializing in computational tools and software for drug discovery and materials science. Its core business revolves around a physics-based computational platform integrating advanced molecular simulation with AI and machine learning, enabling the discovery of novel molecules. The company operates through Software and Drug Discovery segments, offering products like Maestro, LiveDesign, FEP+, Materials Science Suite, and various computational tools, along with custom software development, consulting services, and drug discovery programs.

Schrödinger, Inc. is headquartered in New York, with offices across the United States, Europe, and Asia, serving a global client base. A significant portion of its revenue comes from the United States. Its software is used by pharmaceutical, biotech, tech, chemical, energy, and aerospace firms, as well as academic researchers worldwide.

Schrödinger maintains a strong brand reputation, recognized for its advanced computational platform and ability to transform molecular discovery. The company experiences strong market adoption and customer trust, collaborates with industry leaders, boasts a high customer retention rate, invests significantly in R&D, and acknowledges the importance of cybersecurity.

Schrödinger, Inc. has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors hold a significant portion of the stock, ranging from approximately 63.27% to 97.55% of shares outstanding. Notable individual owners include Bill Gates and David E. Shaw, with CEO Ramy Farid also being an insider owner.